B-condition	0	11	Anastrozole
I-condition	11	12	-
I-condition	12	19	Induced
I-condition	20	26	Carpal
I-condition	27	33	Tunnel
I-condition	34	42	Syndrome
O	42	43	:
O	44	51	Results
O	52	56	From
O	57	60	the
O	61	74	International
O	75	81	Breast
O	82	88	Cancer
O	89	101	Intervention
O	102	107	Study
O	108	110	II
O	111	121	Prevention
O	122	127	Trial
O	127	128	.

O	129	135	Carpal
O	136	142	tunnel
O	143	151	syndrome
O	152	153	(
O	153	156	CTS
O	156	157	)
O	158	164	occurs
O	165	169	when
O	170	173	the
O	174	180	median
O	181	186	nerve
O	187	189	is
O	190	200	compressed
O	201	203	at
O	204	207	the
O	208	213	wrist
O	214	216	in
O	217	220	the
O	221	227	carpal
O	228	234	tunnel
O	234	235	.

O	236	238	It
O	239	242	has
O	243	247	been
O	248	257	suggested
O	258	262	that
O	263	271	hormonal
O	272	276	risk
O	277	284	factors
O	285	288	may
O	289	291	be
O	292	300	involved
O	301	303	in
O	304	307	the
O	308	320	pathogenesis
O	321	323	of
O	324	327	CTS
O	327	328	,
O	329	332	and
O	333	334	a
O	335	341	higher
O	342	351	incidence
O	352	354	of
O	355	358	CTS
O	359	362	has
O	363	367	been
O	368	376	reported
O	377	379	in
O	380	390	randomized
O	391	399	clinical
O	400	406	trials
O	407	411	with
O	412	421	aromatase
O	422	432	inhibitors
O	433	434	(
O	434	437	AIs
O	437	438	)
O	439	447	compared
O	448	452	with
O	453	462	tamoxifen
O	462	463	.

O	464	468	This
O	469	472	was
O	473	475	an
O	476	487	exploratory
O	488	496	analysis
O	497	499	of
O	500	503	the
O	504	517	International
O	518	524	Breast
O	525	531	Cancer
O	532	544	Intervention
O	545	550	Study
O	551	553	II
O	553	554	,
O	555	556	a
O	557	563	double
O	563	564	-
O	564	569	blind
O	570	580	randomized
O	581	589	clinical
O	590	595	trial
O	596	598	in
O	599	604	which
B-eligibility	605	610	women
I-eligibility	611	613	at
I-eligibility	614	623	increased
I-eligibility	624	628	risk
I-eligibility	629	631	of
I-eligibility	632	638	breast
I-eligibility	639	645	cancer
O	646	650	were
O	651	659	randomly
O	660	668	assigned
O	669	671	to
O	672	679	receive
B-intervention	680	691	anastrozole
O	692	694	or
B-control	695	702	placebo
O	702	703	.

O	704	708	This
O	709	711	is
O	712	715	the
O	716	721	first
O	722	728	report
O	729	731	of
O	732	736	risk
O	737	744	factors
O	745	748	for
O	749	752	and
O	753	768	characteristics
O	769	771	of
O	772	775	CTS
O	776	778	in
O	779	784	women
O	785	791	taking
O	792	794	an
O	795	797	AI
O	798	800	in
O	801	802	a
O	803	810	placebo
O	810	811	-
O	811	821	controlled
O	822	827	trial
O	827	828	.

O	829	836	Overall
O	836	837	,
O	838	840	96
O	841	853	participants
O	854	858	with
B-outcome	859	862	CTS
O	863	867	were
O	868	876	observed
O	876	877	:
B-intervention-participants	878	880	65
I-intervention-participants	881	882	(
I-intervention-participants	882	883	3
I-intervention-participants	883	884	.
I-intervention-participants	884	885	4
I-intervention-participants	885	886	%
I-intervention-participants	886	887	)
O	888	890	in
O	891	894	the
O	895	906	anastrozole
O	907	910	arm
O	911	914	and
B-control-participants	915	917	31
I-control-participants	918	919	(
I-control-participants	919	920	1
I-control-participants	920	921	.
I-control-participants	921	922	6
I-control-participants	922	923	%
I-control-participants	923	924	)
O	925	927	in
O	928	931	the
O	932	939	placebo
O	940	943	arm
O	944	945	(
O	945	949	odds
O	950	955	ratio
O	955	956	,
O	957	958	2
O	958	959	.
O	959	961	16
O	962	963	[
O	963	964	1
O	964	965	.
O	965	967	40
O	968	970	to
O	971	972	3
O	972	973	.
O	973	975	33
O	975	976	]
O	976	977	;
O	978	979	P
O	980	981	<
O	982	983	.
O	983	986	001
O	986	987	)
O	987	988	.

O	989	992	Ten
O	993	1005	participants
O	1006	1010	were
O	1011	1019	reported
O	1020	1022	as
O	1023	1029	having
B-outcome	1030	1036	severe
I-outcome	1037	1040	CTS
O	1040	1041	,
O	1042	1044	of
O	1045	1050	which
B-iv-bin-abs	1051	1056	eight
O	1057	1061	were
O	1062	1068	taking
O	1069	1080	anastrozole
O	1081	1082	(
O	1082	1083	P
O	1084	1085	=
O	1086	1087	.
O	1087	1089	08
O	1089	1090	)
O	1090	1091	.

B-iv-bin-abs	1092	1100	Eighteen
O	1101	1106	women
O	1107	1108	(
B-iv-bin-percent	1108	1109	0
I-iv-bin-percent	1109	1110	.
I-iv-bin-percent	1110	1111	9
I-iv-bin-percent	1111	1112	%
O	1112	1113	)
O	1114	1116	in
O	1117	1120	the
O	1121	1132	anastrozole
O	1133	1136	arm
O	1137	1140	and
B-cv-bin-abs	1141	1144	six
O	1145	1150	women
O	1151	1152	(
B-cv-bin-percent	1152	1153	0
I-cv-bin-percent	1153	1154	.
I-cv-bin-percent	1154	1155	3
I-cv-bin-percent	1155	1156	%
O	1156	1157	)
O	1158	1160	in
O	1161	1164	the
O	1165	1172	placebo
O	1173	1176	arm
B-outcome	1177	1185	reported
I-outcome	1186	1194	surgical
I-outcome	1195	1207	intervention
O	1207	1208	,
O	1209	1214	which
O	1215	1218	was
O	1219	1232	significantly
O	1233	1242	different
O	1243	1244	(
O	1244	1248	odds
O	1249	1254	ratio
O	1254	1255	,
O	1256	1257	3
O	1257	1258	.
O	1258	1260	06
O	1261	1262	[
O	1262	1263	1
O	1263	1264	.
O	1264	1266	21
O	1267	1269	to
O	1270	1271	7
O	1271	1272	.
O	1272	1274	72
O	1274	1275	]
O	1275	1276	,
O	1277	1278	P
O	1279	1280	=
O	1281	1282	.
O	1282	1285	018
O	1285	1286	)
O	1286	1287	.

O	1288	1291	Six
O	1292	1297	women
B-outcome	1298	1310	discontinued
O	1311	1315	with
O	1316	1319	the
O	1320	1329	allocated
O	1330	1339	treatment
O	1340	1347	because
O	1348	1350	of
O	1351	1354	the
O	1355	1360	onset
O	1361	1363	of
O	1364	1367	CTS
O	1367	1368	.

O	1369	1374	Apart
O	1375	1379	from
O	1380	1389	treatment
O	1390	1400	allocation
O	1400	1401	,
O	1402	1403	a
O	1404	1408	high
O	1409	1413	body
O	1414	1418	mass
O	1419	1424	index
O	1425	1428	and
O	1429	1431	an
O	1432	1433	a
O	1434	1439	prior
O	1440	1446	report
O	1447	1449	of
O	1450	1465	musculoskeletal
O	1466	1474	symptoms
O	1475	1480	after
O	1481	1486	trial
O	1487	1492	entry
O	1493	1497	were
O	1498	1501	the
O	1502	1506	only
O	1507	1512	other
O	1513	1517	risk
O	1518	1525	factors
O	1526	1529	for
O	1530	1533	CTS
O	1534	1544	identified
O	1545	1547	in
O	1548	1553	these
O	1554	1568	postmenopausal
O	1569	1574	women
O	1574	1575	.

O	1576	1579	The
O	1580	1583	use
O	1584	1586	of
O	1587	1598	anastrozole
O	1599	1602	was
O	1603	1613	associated
O	1614	1618	with
O	1619	1620	a
O	1621	1627	higher
O	1628	1637	incidence
O	1638	1640	of
O	1641	1644	CTS
O	1645	1648	but
O	1649	1652	few
O	1653	1665	participants
O	1666	1674	required
O	1675	1682	surgery
O	1682	1683	.

O	1684	1691	Further
O	1692	1706	investigations
O	1707	1710	are
O	1711	1720	warranted
O	1721	1725	into
O	1726	1729	the
O	1730	1734	risk
O	1735	1742	factors
O	1743	1746	and
O	1747	1756	treatment
O	1757	1759	of
O	1760	1762	AI
O	1762	1763	-
O	1763	1770	induced
O	1771	1774	CTS
O	1774	1775	.
